Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment.

Patients with chronic renal impairment (CRI) are at greatly increased risk for premature vascular disease; however, little is known about its evolution. This paper describes a cohort of patients with CRI and reports study design, baseline demographic and biochemical data, and comparisons with two contemporaneous age- and sex-matched control groups, one with established coronary artery disease and the other without overt vascular disease. Among 369 individuals (median age, 63 years; range, 18 to 88 years; 67% men) with CRI, 34% had a history of vascular disease and 21% had electrocardiographic left ventricular hypertrophy (LVH). Even in those with mild renal impairment (serum creatinine < 2.1 mg/dL), approximately one third had vascular disease and 12% had LVH. A history of hypertension was present in 76% of the CRI group, but as compared with controls, systolic and diastolic blood pressures were not elevated. Low-density lipoprotein (LDL) cholesterol concentration also was not elevated, but CRI was associated with elevated serum triglyceride and plasma homocysteine levels and reduced high-density lipoprotein (HDL) cholesterol, hemoglobin, and serum albumin concentrations. Across the spectrum of CRI, more severe renal dysfunction was associated with lower levels of diastolic blood pressure, LDL and HDL cholesterol, albumin, and hemoglobin, but increased levels of plasma homocysteine. This cross-sectional analysis shows that vascular disease is common in individuals with mild CRI attending a nephrology program and also suggests trends in the levels of a number of potential vascular risk factors with respect to severity of renal dysfunction. These results will be further quantified in a prospective biennial follow-up.

[1]  S. Wannamethee,et al.  Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. , 1997, Stroke.

[2]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[3]  P. Nilsson-ehle,et al.  The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. , 1996, Scandinavian journal of clinical and laboratory investigation.

[4]  D. Wheeler,et al.  Low-density lipoprotein subfraction profiles in chronic renal failure. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  M. Sokolow,et al.  The ventricular complex in right ventricular hypertrophy as obtained by unipolar precordial and limb leads. , 1949, American heart journal.

[7]  D. Serur,et al.  Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  D. Bates,et al.  Relationship between hematocrit and renal function in men and women. , 2001, Kidney international.

[9]  G. London,et al.  Atherosclerosis and arteriosclerosis in chronic renal failure. , 1997, Kidney international.

[10]  P. Barie,et al.  Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. , 1996, Critical care medicine.

[11]  David C. Murray,et al.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.

[12]  Colin Baigent,et al.  Premature cardiovascular disease in chronic renal failure , 2000, The Lancet.

[13]  A. Hutchison,et al.  Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. , 1988, Clinical chemistry.

[14]  W. Bartlett,et al.  Measurement of plasma total homocysteine by HPLC with coulometric detection. , 1999, Clinical chemistry.

[15]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[16]  M. Salvadori,et al.  Lipids and apolipoproteins change during the progression of chronic renal failure. , 1992, Clinical nephrology.

[17]  N. Rifai,et al.  Three generations of high-density lipoprotein cholesterol assays compared with ultracentrifugation/dextran sulfate-Mg2+ method. , 1997, Clinical chemistry.

[18]  S. Volpato,et al.  Acute Phase Markers Are Associated with Reduced Plasma Lipid Levels in a Population of Hospitalized Elderly Patients , 1999, Gerontology.

[19]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[20]  W. März,et al.  Lipoproteins and apolipoproteins during the progression of chronic renal disease. , 1988, Nephron.

[21]  P. Attman,et al.  Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis. , 1991, Nephron.

[22]  I. Rosenberg,et al.  Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[23]  B. Scribner,et al.  Accelerated atherosclerosis in prolonged maintenance hemodialysis. , 1974, The New England journal of medicine.

[24]  A. Irish,et al.  Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. , 1998, Atherosclerosis.

[25]  J. Gore,et al.  Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. , 1984, The American journal of cardiology.